Ate-Bev Early Response Prediction Model in Advanced HCC

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Feb 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a combination treatment of atezolizumab and bevacizumab works for patients with advanced liver cancer, known as hepatocellular carcinoma (HCC). The goal is to develop a way to predict how patients will respond to this treatment early on, which can help doctors make better decisions about their care. While previous treatments have not been as effective, this new combination has shown promise, and the researchers want to learn more about how to evaluate its success compared to using each drug alone.

To participate in this trial, patients need to be diagnosed with advanced HCC and scheduled to start the atezolizumab-bevacizumab treatment as their first therapy. They also need to be willing to join the study. However, patients with severe allergies to contrast materials used in imaging tests or those with serious health issues may not be eligible. If you join this study, you can expect to undergo regular evaluations to monitor your response to the treatment while contributing to important research that could help future patients with liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy
• • Patients willing to participate in this study
• Exclusion Criteria:
• • Individuals with a history of severe contrast allergy
• • Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)